{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:58:29Z","timestamp":1791374309771,"version":"4.3.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.10.002","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:18:43Z","timestamp":1768378723000},"page":"179-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patients"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-2366","authenticated-orcid":false,"given":"Jelani K.","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Koester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-6617","authenticated-orcid":false,"given":"Thorsten M.","family":"Leucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas S.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.jacl.2025.10.002_bib0001","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: a systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0002","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2025.10.002_bib0003","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","article-title":"Respiratory management of the patient with duchenne muscular dystrophy","volume":"142","author":"Sheehan","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0004","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41598-022-07814-z","article-title":"A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain","volume":"12","author":"Llamosas-Falc\u00f3n","year":"2022","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.jacl.2025.10.002_bib0005","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1161\/CIR.0000000000000526","article-title":"Management of cardiac involvement associated with neuromuscular diseases: A scientific statement from the American Heart Association","volume":"136","author":"Feingold","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2025.10.002_bib0007","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1161\/01.CIR.94.12.3168","article-title":"Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy","volume":"94","author":"Melacini","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and stroke statistics: A report of US and global data from the American Heart Association","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0009","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.pmr.2005.08.014","article-title":"Obesity, physical activity, and the metabolic syndrome in adult neuromuscular disease","volume":"16","author":"Kilmer","year":"2005","journal-title":"Phys Med Rehabil Clin North Am"},{"issue":"9307","key":"10.1016\/j.jacl.2025.10.002_bib0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0011","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0035-1558982","article-title":"Dystrophinopathies","volume":"35","author":"Brandsema","year":"2015","journal-title":"Semin Neurol"},{"issue":"10213","key":"10.1016\/j.jacl.2025.10.002_bib0012","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"issue":"1111","key":"10.1016\/j.jacl.2025.10.002_bib0013","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/postgradmedj-2017-135377","article-title":"Duchenne muscular dystrophy: genome editing gives new hope for treatment","volume":"94","author":"Crispi","year":"2018","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mas.21823","article-title":"Characterization of the dystrophin-associated protein complex by mass spectrometry","volume":"43","author":"Canessa","year":"2024","journal-title":"Mass Spectrom Rev"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0016","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0017","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-210640","article-title":"Early gross motor milestones in duchenne muscular dystrophy","volume":"8","author":"Norcia","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0018","first-page":"23","article-title":"Management of scoliosis in patients with duchenne muscular dystrophy and spinal muscular atrophy: a literature review","volume":"9","author":"Garg","year":"2016","journal-title":"J Pediatr Rehabil Med"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0019","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4187\/respcare.00831","article-title":"Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival","volume":"56","author":"Bach","year":"2011","journal-title":"Respir Care"},{"issue":"23","key":"10.1016\/j.jacl.2025.10.002_bib0020","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jacl.2025.10.002_bib0021","series-title":"GeneReviews(\u00ae)","article-title":"Dystrophinopathies","author":"Darras","year":"1993"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCIMAGING.110.960740","article-title":"Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations","volume":"4","author":"Verhaert","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0023","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","article-title":"Antisense oligonucleotide-mediated exon-skipping therapies: Precision medicine spreading from Duchenne muscular dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"JMA J"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0024","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of Eteplirsen in patients with Duchenne muscular dystrophy amenable to Exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol Clin"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0026","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mus.27674","article-title":"Milestones of progression in myotonic dystrophy type 1 and type 2","volume":"66","author":"Hamel","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2025.10.002_bib0027","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-015-0264-3","article-title":"Rhabdomyolysis: a genetic perspective","volume":"10","author":"Scalco","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacl.2025.10.002_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2015.12.013","article-title":"Rhabdomyolysis featuring muscular dystrophies","volume":"361","author":"Lahoria","year":"2016","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.jacl.2025.10.002_bib0029","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.apmr.2004.09.012","article-title":"Metabolic syndrome in neuromuscular disease","volume":"86","author":"Aitkens","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jacl.2020.05.098","article-title":"High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia","volume":"14","author":"White","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0031","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.5114\/aoms.2019.86964","article-title":"Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the very large database of lipids and national health and nutrition examination survey","volume":"16","author":"Sathiyakumar","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jacl.2025.10.002_bib0032","series-title":"Myotonic Dystrophy: Disease Mechanism, Current Management and Therapeutic Development","first-page":"161","article-title":"Lipid metabolism in myotonic dystrophy","author":"Takada","year":"2018"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.002_bib0033","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.24540","article-title":"Metabolic syndrome in patients with myotonic dystrophy type 1","volume":"52","author":"Vujnic","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2025.10.002_bib0034","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.nmd.2016.06.394","article-title":"Liver functional impairment in myotonic dystrophy type 1","volume":"26","author":"Takada","year":"2016","journal-title":"Neuromusc Disord"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamacardio.2019.0911","article-title":"2018 American Heart Association\/American College of Cardiology\/Multisociety Guideline on the management of blood cholesterol-secondary prevention","volume":"4","author":"Grundy","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0036","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2025.10.002_bib0037","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association's Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"10059","key":"10.1016\/j.jacl.2025.10.002_bib0038","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.jacl.2025.10.002_bib0039","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.002_bib0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11883-022-01077-9","article-title":"The management of hypercholesterolemia in patients with neuromuscular disorder","volume":"25","author":"Loh","year":"2023","journal-title":"Curr Atherosclerosis Rep"},{"issue":"8","key":"10.1016\/j.jacl.2025.10.002_bib0041","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042070","article-title":"Statin-induced myopathy: translational studies from preclinical to clinical evidence","volume":"22","author":"Camerino","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0043","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/bph.15678","article-title":"A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: the promotion of myostatin degradation","volume":"179","author":"Sun","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.002_bib0044","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0272-2712(18)30604-8","article-title":"Serum enzymes in disease of skeletal muscle","volume":"9","author":"Rosalki","year":"1989","journal-title":"Clin Lab Med"},{"issue":"17","key":"10.1016\/j.jacl.2025.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010022","article-title":"Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components","volume":"9","author":"Turner","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0047","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.jacl.2025.10.002_bib0048","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.002_bib0049","doi-asserted-by":"crossref","unstructured":"Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association predicting risk of cardiovascular disease EVENTs (PREVENT) equations. Circulation. 0(0). doi:10.1161\/CIRCULATIONAHA.123.067626","DOI":"10.1161\/CIRCULATIONAHA.123.067626"},{"issue":"19","key":"10.1016\/j.jacl.2025.10.002_bib0050","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.002_bib0051","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/mus.20317","article-title":"Nutritional inadequacy in adults with muscular dystrophy","volume":"31","author":"Motlagh","year":"2005","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jacl.2025.10.002_bib0052","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apmr.2005.07.288","article-title":"Impact of a home-based activity and dietary intervention in people with slowly progressive neuromuscular diseases","volume":"86","author":"Kilmer","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"10.1016\/j.jacl.2025.10.002_bib0053","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/nure.12011","article-title":"Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation","volume":"71","author":"Potgieter","year":"2013","journal-title":"Nutr Rev"},{"issue":"5","key":"10.1016\/j.jacl.2025.10.002_bib0054","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"7_Part_2","key":"10.1016\/j.jacl.2025.10.002_bib0055","article-title":"Expert panel perspective","volume":"3","author":"Perpetua","year":"2024","journal-title":"JACC Adv"},{"issue":"14","key":"10.1016\/j.jacl.2025.10.002_bib0056","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am College Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2025.10.002_bib0057","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.002_bib0058","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the national lipid association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"25","key":"10.1016\/j.jacl.2025.10.002_bib0059","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Eng J Med"},{"issue":"15","key":"10.1016\/j.jacl.2025.10.002_bib0060","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jacl.2025.10.002_bib0061","doi-asserted-by":"crossref","unstructured":"Grant JK, Orringer CE. High-intensity statins versus moderate-intensity statin-ezetimibe combination therapy: a patient centered approach. J Clin Lipidol. doi:10.1016\/j.jacl.2024.07.007","DOI":"10.1016\/j.jacl.2024.07.007"},{"key":"10.1016\/j.jacl.2025.10.002_bib0062","doi-asserted-by":"crossref","unstructured":"Kelly FA, de Moraes FCA, L\u00f4bo AdOM, et al. Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis. J Clin Lipidol. doi:10.1016\/j.jacl.2024.07.013","DOI":"10.1016\/j.jacl.2024.07.013"},{"issue":"10349","key":"10.1016\/j.jacl.2025.10.002_bib0063","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jacl.2025.10.002_bib0064","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Eng J Med"},{"issue":"22","key":"10.1016\/j.jacl.2025.10.002_bib0065","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Eng J Med"},{"issue":"10","key":"10.1016\/j.jacl.2025.10.002_bib0066","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","article-title":"Use of proprotein convertase subtilisin\/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series","volume":"71","author":"Tiniakou","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacl.2025.10.002_bib0067","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta","year":"2023","journal-title":"Vasc Health Risk Manag"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:46:41Z","timestamp":1791373601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425004222"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}